A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities

被引:18
作者
Yang, Feifei [1 ,2 ,3 ]
Peng, Shihong [1 ,2 ]
Li, Yunqi [1 ,2 ]
Su, Liqiang [1 ,2 ]
Peng, Yangrui [1 ,2 ]
Wu, Jing [1 ,2 ]
Chen, Huang [1 ,2 ]
Liu, Mingyao [1 ,2 ]
Yi, Zhengfang [1 ,2 ]
Chen, Yihua [1 ,2 ]
机构
[1] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China
[2] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China
[3] Univ Jinan, Sch Biol Sci & Technol, Jinan 250022, Shandong, Peoples R China
基金
中国国家自然科学基金; 高等学校博士学科点专项科研基金;
关键词
CANCER-THERAPY; TUMOR-METASTASIS; MOLECULAR-MECHANISMS; COLONY FORMATION; HDAC INHIBITORS; DESIGN; ACETYLATION; OPTIMIZATION; PERSPECTIVES; DERIVATIVES;
D O I
10.1039/c5ob02250a
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
A series of novel histone deacetylase (HDAC) inhibitors were designed, synthesized and evaluated based on the strategies of a hybrid of the classic pharmacophore of HDAC inhibitors with the thiazolidinone scaffold. Some of the compounds showed potent HDAC1 inhibition with nM IC50 values, more importantly, compound 12i displayed much better anti-metastatic effects than vorinostat (SAHA) against migration of the A549 cell line. Further mechanism exploration implied that compound 12i may inhibit tumor metastasis via modulating the epithelial-mesenchymal transition (EMT) and upregulating the acetylation of alpha-tubulin.
引用
收藏
页码:1727 / 1735
页数:9
相关论文
共 46 条
[1]   Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR [J].
Andrianov, Victor ;
Gailite, Vija ;
Lola, Daina ;
Loza, Einars ;
Semenikhina, Valentina ;
Kalvinsh, Ivars ;
Finn, Paul ;
Petersen, Kamille Dumong ;
Ritchie, James W. A. ;
Khan, Nagma ;
Tumber, Anthony ;
Collins, Laura S. ;
Vadlamudi, Sree M. ;
Bjorkling, Fredrik ;
Sehested, Maxwell .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (03) :1067-1085
[2]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[3]   Association analysis of CβS 844ins68 and MTHFD1 G1958A polymorphisms with Alzheimer's disease in Chinese [J].
Bi, Xiu-Hua ;
Zhao, Hua-Lu ;
Zhang, Zhen-Xin ;
Liu, Qian ;
Zhang, Jun-Wu .
JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (04) :499-503
[4]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[5]   Oxime Amides as a Novel Zinc Binding Group in Histone Deacetylase Inhibitors: Synthesis, Biological Activity, and Computational Evaluation [J].
Botta, Cinzia B. ;
Cabri, Walter ;
Cini, Elena ;
De Cesare, Lucia ;
Fattorusso, Caterina ;
Giannini, Giuseppe ;
Persico, Marco ;
Petrella, Antonello ;
Rondinelli, Francesca ;
Rodriquez, Manuela ;
Russo, Adele ;
Taddei, Maurizio .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (07) :2165-2182
[6]   Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment [J].
Chen, Jhih-Bin ;
Chern, Ting-Rong ;
Wei, Tzu-Tang ;
Chen, Ching-Chow ;
Lin, Jung-Hsin ;
Fang, Jim-Min .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (09) :3645-3655
[7]   Targeting bromodomains: epigenetic readers of lysine acetylation [J].
Filippakopoulos, Panagis ;
Knapp, Stefan .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (05) :339-358
[8]  
Giannini G, 2012, FUTURE MED CHEM, V4, P1439, DOI [10.4155/FMC.12.80, 10.4155/fmc.12.80]
[9]   Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors [J].
Grant, Cliona ;
Rahman, Fand ;
Piekarz, Richard ;
Peer, Cody ;
Frye, Robin ;
Robey, Robert W. ;
Gardner, Erin R. ;
Figg, William D. ;
Batest, Susan E. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) :997-1008
[10]   Histone acetylation and chromatin remodeling [J].
Gregory, PD ;
Wagner, K ;
Hörz, W .
EXPERIMENTAL CELL RESEARCH, 2001, 265 (02) :195-202